Citigroup Maintains Buy Rating on Amylyx, Raises Target to $39
Citigroup raised its Amylyx Pharmaceuticals price target to $39 per share from $32 while maintaining its Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.